Patents by Inventor David M. Knight

David M. Knight has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5877006
    Abstract: Platelet-specific, chimeric immunoglobulin and immunoglobulin fragments are described. The chimeric molecules are made up of a nonhuman antigen binding region and a human constant region. Preferred immunoglobulins are specific for glycoprotein IIb/IIIa receptor in its complexed form; they block ligand binding to the receptor and prevent platelet aggregation. The immunoglobulins are useful in anti-thrombotic therapy when administered alone or in conjunction with thrombolytic agents, as well as in thrombus imaging.
    Type: Grant
    Filed: May 17, 1995
    Date of Patent: March 2, 1999
    Assignees: Centocor, Inc., The Research Foundation of State of New York
    Inventors: Barry S. Coller, David M. Knight
  • Patent number: 5770198
    Abstract: Platelet-specific, chimeric immunoglobulin and immunoglobulin fragments are described. The chimeric molecules are made up of a nonhuman antigen binding region and a human constant region. Preferred immunoglobulins are specific for glycoprotein IIb/IIIa receptor in its complexed form; they block ligand binding to the receptor and prevent platelet aggregation. The immunoglobulins are useful in anti-thrombotic therapy when administered alone or in conjunction with thrombolytic agents, as well as in thrombus imaging.
    Type: Grant
    Filed: January 17, 1995
    Date of Patent: June 23, 1998
    Assignees: The Research Foundation of the State of New York, Centocor, Inc.
    Inventors: Barry S. Coller, David M. Knight
  • Patent number: 4910132
    Abstract: A virus-free assay to identify agents that interfere with the life cycle of HIV which comprises: (1) expressing in mammalian cells in the presence or absence of one or more of said agents, HIV gp120, the gene product of HIV tat, the gene product of HIV art/trs, all under the control of an HIV LTR promoter, and a control protein, not under the control of the HIV LTR promoter, such that infectious HIV particles are not produced; (2) quantitating the amount of the gp120 produced relative to the amount of control protein produced; and (3) comparing the relative amount of the gp120 produced in the presence of said one or more agents to the relative amount of the gp120 produced in the absence of said one or more agents.
    Type: Grant
    Filed: May 12, 1987
    Date of Patent: March 20, 1990
    Assignee: Centocor
    Inventors: David M. Knight, John Ghrayeb